At the end of the latest market close, Onconova Therapeutics Inc. (ONTX) was valued at $0.34. In that particular session, Stock kicked-off at the price of $0.321 while reaching the peak value of $0.348 and lowest value recorded on the day was $0.3185. The stock current value is $0.32.
Recently in News on November 23, 2020, Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300. U.S. Phase 1 trial patient enrollment to begin in the first half of 2021. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Onconova Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.5600 on 07/21/20, with the lowest value was $0.1901 for the same time period, recorded on 09/04/20.
Onconova Therapeutics Inc. (ONTX) full year performance was 23.44%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Onconova Therapeutics Inc. shares are logging -79.17% during the 52-week period from high price, and 70.96% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.19 and $1.56.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3398112 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Onconova Therapeutics Inc. (ONTX) recorded performance in the market was -12.27%, having the revenues showcasing 47.89% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 58.20M, as it employees total of 25 workers.
Market experts do have their say about Onconova Therapeutics Inc. (ONTX)
During the last month, 0 analysts gave the Onconova Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.4487, with a change in the price was noted -0.8053. In a similar fashion, Onconova Therapeutics Inc. posted a movement of -70.64% for the period of last 100 days, recording 16,204,740 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ONTX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Onconova Therapeutics Inc. (ONTX)
Raw Stochastic average of Onconova Therapeutics Inc. in the period of last 50 days is set at 46.42%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 43.37%. In the last 20 days, the company’s Stochastic %K was 40.14% and its Stochastic %D was recorded 37.07%.
Bearing in mind the latest performance of Onconova Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -12.27%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -44.07%, alongside a boost of 23.44% for the period of the last 12 months. The shares increased approximately by 4.15% in the 7-day charts and went down by 24.35% in the period of the last 30 days. Common stock shares were driven by 47.89% during last recorded quarter.